In one of the most consequential healthcare deals of the year, President Trump’s new drug-pricing pact with Eli Lilly and Novo Nordisk slashes the cost of blockbuster GLP-1 drugs like Wegovy and Zepbound, turning a luxury medicine into a mainstream benefit—and forcing Ro, Hims, Mochi Health, and other telehealth players to rethink their most lucrative […]
